ClinVar Miner

Submissions for variant NM_005373.3(MPL):c.189C>A (p.Tyr63Ter)

dbSNP: rs1373623383
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001174802 SCV001338148 likely pathogenic Congenital amegakaryocytic thrombocytopenia 2020-02-10 criteria provided, single submitter clinical testing Variant summary: MPL c.189C>A (p.Tyr63X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 251164 control chromosomes (gnomAD). c.189C>A has been reported in the literature in compound heterozygous individuals affected with Congenital Amegakaryocytic Thrombocytopenia (Savoia_2007, Chung_2011). These data indicate that the variant may be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as likely pathogenic.
Genetic Services Laboratory,University of Chicago RCV001819878 SCV002068996 pathogenic not provided 2018-05-01 criteria provided, single submitter clinical testing DNA sequence analysis of the MPL gene demonstrated a sequence change, c.189C>A, which results in the creation of a premature stop codon at amino acid position 63, p.Tyr63*. This pathogenic sequence change is predicted to result in an abnormal transcript, which may be degraded, or may lead to the production of a truncated MPL protein with potentially abnormal function. This pathogenic sequence change has previously been described in the compound heterozygous state in a patient with congenital amegakaryocytic thrombocytopenia (Chung et. al., 2011). This pathogenic sequence change in the heterozygous state is not sufficient to cause this patient's thrombocytopenia. This patient is a germline carrier of this sequence change. Heterozygous germline or somatic pathogenic variants in the MPL gene have been described in the patients with thrombocythemia [OMIM#601977]. Somatic pathogenic variants in MPL also cause myelofibrosis [OMIM#254450]. Homozygous or compound heterozygous pathogenic variants in the MPL gene have been described in the patients with congenital amegakaryocytic thrombocytopenia [OMIM#604498].

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.